Lindahl advises Senzime AB in connection with listing on Nasdaq Stockholm’s Main Market

Lindahl acted as legal advisor to Senzime AB (publ) in connection with the company’s listing transfer from Nasdaq First North Growth Market to Nasdaq Stockholm’s Main Market. Trading on Nasdaq Stockholm commenced on 30 June 2021.

Senzime develops and markets unique CE- and FDA-approved medical technology solutions, driven by proprietary algorithms and sensors for point-of-care monitoring during anesthesia. Senzime’s TetraGraph® system digitally and continuously measures the degree of neuromuscular blockade to prevent complications, improve clinical precision, and simplify workflows in healthcare. Senzime’s vision is a world without anesthesia-related complications and safe recovery for all patients.

The Lindahl team consisted of Mattias Prage, Helena Lindbäck, Andreas Mellberg, Amanda Sjöberg, and Erik Vikström. In addition, several other colleagues contributed their expertise to various aspects of the project.